BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme

Kyle LaHucik

Senior Reporter

BioMarin, multiple quarters into its portfolio refinement, is inking a small acquisition for a rare disease therapy about two years before a potential regulatory approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

HHS can require approval for drugmakers to apply 340B rebate models, court rules

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Bio­Marin makes Phase 3 buy, pay­ing $270M for rare dis­ease out­fit In­ozyme

Senior Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme